Your browser doesn't support javascript.
loading
Lifting COVID-19 mitigation measures in Spain (May-June 2020).
Monge, Susana; Latasa Zamalloa, Pello; Sierra Moros, María José; Pérez Olaso, Oscar; García San Miguel, Lucía; Varela, Carmen; Rivera Ariza, Silvia; Vázquez Torres, María C; Olmedo Lucerón, María Del Carmen; González Yuste, Paloma; Soler Crespo, Pilar; Segura Del Pozo, Javier; Gullón, Pedro; Carrasco, José Miguel; Martínez Sánchez, Elena Vanessa; Redondo Bravo, Lidia; Pichiule Castañeda, Myriam; Purriños Hermida, María Jesús; Hervada Vidal, Xurxo; Huerta Gonzalez, Ismael; Margolles, Mario; Vanaclocha Luna, Hermelinda; Ramalle Gómara, Enrique; Pérez Martín, Jaime Jesús; Chirlaque López, María Dolores; López Fernández, María Jesús; Lorusso, Nicola; Carmona Ubago, Alberto; Rivas Perez, Ana; Ramos Marin, Violeta; Criado Alvarez, Juan José; Castrillejo Pérez, Daniel; Góméz Anés, Atanasio A; Frontera, Marga; Macias Rodriguez, Pedro; Álvarez León, Eva Elisa; Díaz Casañas, Miriam; Lopaz Perez, Maria Angeles; Alonso Pérez de Ágreda, Juan Pablo; Navas Gutierrez, Paloma; Rosell Aguilar, Ignacio; Arteagoitia Axpe, Jose María; Gonzalez Carril, Fernando; Aparicio Azcárraga, Pilar; Simón Soria, Fernando; Suarez Rodríguez, Berta.
Afiliación
  • Monge S; Ministry of Health, Madrid, Spain. Electronic address: smonge@mscbs.es.
  • Latasa Zamalloa P; Ministry of Health, Madrid, Spain.
  • Sierra Moros MJ; Ministry of Health, Madrid, Spain.
  • Pérez Olaso O; Ministry of Health, Madrid, Spain.
  • García San Miguel L; Ministry of Health, Madrid, Spain.
  • Varela C; National Centre of Epidemiology, Instituto de Salud Carlos III, CIBER Epidemiología y Salud Pública, Madrid, Spain.
  • Rivera Ariza S; Ministry of Health, Madrid, Spain.
  • Vázquez Torres MC; Ministry of Health, Madrid, Spain.
  • Olmedo Lucerón MDC; Ministry of Health, Madrid, Spain.
  • González Yuste P; Ministry of Health, Madrid, Spain.
  • Soler Crespo P; Ministry of Health, Madrid, Spain.
  • Segura Del Pozo J; Madrid Salud (Madrid Council Public Health Agency), Madrid, Spain.
  • Gullón P; APLICA Investigación y Traslación Soc Coop Mad, Madrid, Spain.
  • Carrasco JM; APLICA Investigación y Traslación Soc Coop Mad, Madrid, Spain.
  • Martínez Sánchez EV; Ministry of Health, Madrid, Spain.
  • Redondo Bravo L; Ministry of Health, Madrid, Spain.
  • Pichiule Castañeda M; Ministry of Health, Madrid, Spain.
  • Purriños Hermida MJ; General Directorate of Public Health, Autonomous Community of Galicia, Spain.
  • Hervada Vidal X; General Directorate of Public Health, Autonomous Community of Galicia, Spain.
  • Huerta Gonzalez I; General Directorate of Public Health, Principality of Asturias, Spain.
  • Margolles M; General Directorate of Public Health, Principality of Asturias, Spain.
  • Vanaclocha Luna H; Subdirectorate of Epidemiology and Public Health Surveillance, Autonomous Community of Valencia, Spain.
  • Ramalle Gómara E; General Directorate of Public Health, Consumption and Care, Autonomous Community of La Rioja, Spain.
  • Pérez Martín JJ; General Directorate of Public Health and Addictions, IMIB-Arrixaca. Murcia University, Region of Murcia, Spain.
  • Chirlaque López MD; General Directorate of Public Health and Addictions, IMIB-Arrixaca. Murcia University, Region of Murcia, Spain.
  • López Fernández MJ; Extremadura Health Service, Autonomous Community of Extremadura, Spain.
  • Lorusso N; General Directorate of Public Health and Pharmacy, Autonomous Community of Andalusia, Spain.
  • Carmona Ubago A; General Directorate of Public Health and Pharmacy, Autonomous Community of Andalusia, Spain.
  • Rivas Perez A; Ministry of Health, Autonomous City of Ceuta, Spain.
  • Ramos Marin V; Ministry of Health, Autonomous City of Ceuta, Spain.
  • Criado Alvarez JJ; Health Sciences Institute of Castile-La Mancha, Autonomous Community of Castile-La Mancha, Spain.
  • Castrillejo Pérez D; General Directorate of Public Health and Consumption, Autonomous City of Melilla, Spain.
  • Góméz Anés AA; General Directorate of Public Health and Consumption, Autonomous City of Melilla, Spain.
  • Frontera M; Ministry of Health, Balearic Islands, Spain.
  • Macias Rodriguez P; Ministry of Health, Balearic Islands, Spain.
  • Álvarez León EE; General Directorate of Public Health, Canary Islands, Spain.
  • Díaz Casañas M; General Directorate of Public Health, Canary Islands, Spain.
  • Lopaz Perez MA; General Directorate of Public Health, Autonomous Community of Madrid, Spain.
  • Alonso Pérez de Ágreda JP; General Directorate of Public Health, Autonomous Community of Aragón, Spain.
  • Navas Gutierrez P; General Directorate of Public Health, Autonomous Community of Cantabria, Spain.
  • Rosell Aguilar I; General Directorate of Public Health, Autonomous Community of Castilla y León, Spain.
  • Arteagoitia Axpe JM; General Directorate of Public Health and Addictions, Basque Country, Spain.
  • Gonzalez Carril F; General Directorate of Public Health and Addictions, Basque Country, Spain.
  • Aparicio Azcárraga P; Ministry of Health, Madrid, Spain.
  • Simón Soria F; Ministry of Health, Madrid, Spain.
  • Suarez Rodríguez B; Ministry of Health, Madrid, Spain.
Article en En | MEDLINE | ID: mdl-36621243
ABSTRACT

INTRODUCTION:

The state of alarm was declared in Spain due to the COVID-19 epidemic on March 14, 2020, and established population confinement measures. The objective is to describe the process of lifting these mitigation measures.

METHODS:

The Plan for the Transition to a New Normality, approved on April 28, contained four sequential phases with progressive increase in socio-economic activities and population mobility. In parallel, a new strategy for early diagnosis, surveillance and control was implemented. A bilateral decision mechanism was established between the Spanish Government and the autonomous communities (AC), guided by a set of qualitative and quantitative indicators capturing the epidemiological situation and core capacities. The territorial units were established ad-hoc and could be from Basic Health Zones to entire AC.

RESULTS:

The process run from May 4 to June 21, 2020. AC implemented plans for reinforcement of core capacities. Incidence decreased from a median (50% of territories) of 7.4 per 100,000 in 7 days at the beginning to 2.5 at the end. Median PCR testing increased from 53% to 89% of suspected cases and PCR total capacity from 4.5 to 9.8 per 1000 inhabitants weekly; positivity rate decreased from 3.5% to 1.8%. Median proportion of cases with traced contacts increased from 82% to 100%.

CONCLUSION:

Systematic data collection, analysis, and interterritorial dialogue allowed adequate process control. The epidemiological situation improved but, mostly, the process entailed a great reinforcement of core response capacities nation-wide, under common criteria. Maintaining and further reinforcing capacities remained crucial for responding to future waves.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: COVID-19 Tipo de estudio: Prognostic_studies / Qualitative_research / Screening_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Enferm Infecc Microbiol Clin (Engl Ed) Año: 2023 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: COVID-19 Tipo de estudio: Prognostic_studies / Qualitative_research / Screening_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Enferm Infecc Microbiol Clin (Engl Ed) Año: 2023 Tipo del documento: Article